Chunfeng Qu, MD, PhD
Professor & Director
Department of the Immunology
Principle Investigator of the State
Chinese Academy of Medical
Sciences/Peking Union Medical College
17 Panjiayuan Nanli, Chaoyang District
Beijing 100021, China
Dr. Qu received her MD from Weifang Medical College in Shandong Province, and completed her PhD (major: Immunology) in 1999 at Peking Union Medical College in Beijing, China. She received her postdoctoral training supervised by Dr. Gwendalyn J. Randolph and Dr. Xiu-Min Li at Mount Sinai School of Medicine in New York, USA. In January 2008 she took the position as the Professor of Immunology at Cancer Hospital/Institute, Chinese Academy of Medical Sciences & Peking Union Medical College in Beijing, Chins. She has published more than 25 research papers in Peer-reviewed journals.
Dr. Qu investigated how the human blood monocytes differentiated into antigen presenting dendritic cells in response to influenza A virus in peripheral tissues and the role of the monocyte-derived cells for antigen presentation. Recent years, she investigated how to induce the immune responses to the viral proteins of hepatitis B virus (HBV) after chronic virus infection, the effect of vaccination with HBV vaccine in population and the potential defects of the HBV vaccines in controlling the chronic HBV infection. Her current research is focusing on the prevention of HBV-induced liver cancer by immunological approaches.
Her research interests includes: Developing therapeutic vaccine including cancer vaccine,vaccine adjuvants, HBV-host interaction and T cell priming and memory maintaining.
HONORS AND AWARDS
• (2010), Outstanding Researcher of Peking Union Medical College. Beijing China
• (2009), Research Scholarship of the Ministry of Education of PRC
• (2003), Keystone Symposia Scholarship winner: Dendritic Cells: the interfaces with immunobiology and Medicine. Keystone, CO. USA
1. Xu L, Yi HG, Wu Z, et al. Activation of mucosal mast cells promotes inflammation-related colon cancer development through recruiting and modulating inflammatory CD11b+Gr1+ cells. Cancer Lett. 2015; 364(2): 173-180. doi: 10.1016/j.canlet.2015.05.014
2. Qu C, Chen T, Fan C, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med. 2014; 11(12): e1001774.doi: 10.1371/journal.pmed.1001774
3. Wang Y, Chen K, Wu Z, et al. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice. Int J Infect Dis. 2014; 29: 31-36. doi: 10.1016/j.ijid.2014.07.015
4. Lu LL, Chen BX, Wang J, et al. Maternal transmission risk and antibody levels against hepatitis B virus e antigen in pregnant women. Int J Infect Dis. 2014; 28C: 41-44.doi: 10.1016/j.ijid.2014.07.028
5. Zhang X, Gao L, Liang X, et al. HBV preS2 transactivates FOXP3 expression in malignant hepatocytes. Liver Int. 2014. doi: 10.1111/liv.12642
6. Qu C, Brinck-Jensen NS, Zang M, Chen K. Monocyte-derived dendritic cells: targets as potent antigen-presenting cells for the design of vaccines against infectious diseases. Int J Infect Dis. 2014 Feb;19:1-5. doi: 10.1016/j.ijid.2013.09.023.
7. Sun ZT, Chen TY, Thorgeirsson SS, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis. 2013; 34(8): 1800-1805. doi: 10.1093/carcin/bgt007
8. Zhang T, Cai J, Chang J, et al. Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma. Hum mol genet. 2013; 22(6）1262-1269doi: 10.1093/hmg/dds513
9. Wu J, Du J, Liu L, et al. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS One. 2012; 7(12): e50035doi: 10.1371/journal.pone.0050035.
10. Zhu CL, Liu P, Chen T, et al. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine. 2011; 29(37): 7835-41doi: 10.1016/j.vaccine.2011.07.098
11. Du J, Wu Z, Ren S, et al. TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity. Vaccine. 2010; 28(37): 5986-5992.doi: 10.1016/j.vaccine.2010.06.117
12. Xu L, Wei Y, Chen T, et al. Occult HBV infection in anti-HBs-positive young adults after neonatal HB vaccination. Vaccine. 2010; 28(37): 5986-5992. doi: 10.1016/j.vaccine.2010.06.106.
13. Ren SR, Xu L, Wu Z, J, Gao MH, Qu C. Exogenous dendritic cell homing to draining lymph nodes can be boosted by mast cell degranulation. Cellular Immunology. 2010; 263: 204-211. doi: 10.1016/j.cellimm.2010.03.017
14. Qu C, Nguyen VA, Merad M, Randolph GJ. MHC class I/peptide transfer between dendritic cells overcomes poor cross-presentation by monocyte-derived APCs that engulf dying cells. J Immunol. 2009; 182(6): 3650-3659. doi: 10.4049/jimmunol.0801532
15. Randolph GJ, Jakubzick C, Qu C. Antigen presentation by monocytes and monocyte-derived cells. Curr Opin Immunol. 2008; 20(1): 52-60. doi: 10.1016/j.coi.2007.10.010
16. Qu C, Edwards EW, Tacke F, et al. Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. J Exp Med. 2004; 200(10): 1231-1241. doi: 10.1084/jem.20032152
17. Qu C, Moran TM, Randolph GJ. Autocrine type I IFN and contact with endothelium promote the presentation of influenza A virus by monocyte-derived APC. J Immunol. 2003; 170(2): 1010-1018. doi: 10.4049/jimmunol.170.2.1010
18. Wang Y, Lu L-L, Wang D, Qu C. Herd immunity conferred by hepatitis B vaccination increases the protection efficacy against hepatitis B virus infection. Vaccin Res Open J. 2016; 1(1): 10-12. doi: 10.17140/VROJ-1- 103